Tidal Investments’s Protagonist Therapeutics PTGX Stock Holding History

Tidal Investments’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.16M	Buy	+11,034	New	+$977K	﹤0.01%	1395
2025 Q4	–	Sell	-8,945	Closed	-$594K	–	2292
2025 Q3	$594K	Sell	8,945 -14,832	-62%	-$843K	﹤0.01%	1478
2025 Q2	$1.31M	Buy	23,777 +4,367	+22%	+$210K	0.01%	905
2025 Q1	$939K	Sell	19,410 -1,602	-8%	-$67.1K	0.01%	1000
2024 Q4	$811K	Sell	21,012 -1,050	-5%	-$45.8K	0.01%	1114
2024 Q3	$993K	Hold	22,062	–	–	0.01%	991
2024 Q2	$764K	Buy	+22,062	New	+$646K	0.01%	1041

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Tidal Investments's PTGX Position: Q1 2026 in Review

Tidal Investments opened a new position in Protagonist Therapeutics (PTGX) in Q1 2026: 11,034 shares worth $1.16M. The stake represents ﹤0.01% of the portfolio and ranks #1395 among its holdings. This is a return to the name: Tidal Investments previously reported a position in PTGX as recently as Q3 2025.

Tidal Investments first reported a position in PTGX in Q2 2024 and has held it in 7 quarters since. The position peaked at $1.31M in Q2 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Tidal Investments held 11,034 shares of Protagonist Therapeutics worth $1.16M as of Q1 2026.
Protagonist Therapeutics was a new Tidal Investments position in Q1 2026.
Protagonist Therapeutics made up ﹤0.01% of Tidal Investments's portfolio in Q1 2026, its #1395 holding.
Tidal Investments first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 7 quarters since.
Tidal Investments's Protagonist Therapeutics position peaked at $1.31M in Q2 2025.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Tidal Investments's 13F filing for Q1 2026, filed 15 May 2026.